Risk of cancer in patients with heart failure who use digoxin

a 10-year follow-up study and cell-based verification

Min-Huey Chung, Yi Wen Wang, Yung Lung Chang, Shih Ming Huang, Wei Shiang Lin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Heart failure (HF) is the leading cause of death in the world and digoxin remains one of the oldest therapies for HF. However, its safety and efficacy have been controversial since its initial use and there is uncertainty about its long-term efficacy and safety. Recently, the repositioning of cardiac glycosides is to function in anti-tumor activity via multiple working pathways. It is interesting to compare the potential effects of digoxin in clinical patients and cell lines. First, we analyze patient information retrieved from the National Health Insurance Research database of Taiwan between January 1, 2000 and December 31, 2000. This retrospective study included a study cohort (1,219 patients) and a comparison cohort. Our analytical data suggested that patients taking digoxin are at an increased risk of cancers, including breast, liver, and lung cancers, during the 10-year follow-up period. In contrast to the anti-tumor function of digoxin, we further examined the potential pathway of digoxin via the cell-based strategy using several breast cancer cell lines, including MCF-7, BT-474, MAD-MB-231, and ZR-75-1. Digoxin consistently exerted its cytotoxicity to these four cell lines with various range of concentration. However, the proliferation of ZR-75-1 cells was the only cell lines induced by digoxin and the others were dramatically suppressed by digoxin. The responsiveness of SRSF3 to digoxin might be involved with cell-type differences. In summary, we combined a cohort study for digoxin treatment for HF patients with a cell-based strategy that addresses the translation issue, which revealed the complexity of personalized medicine.

Original languageEnglish
JournalOncotarget
DOIs
Publication statusE-pub ahead of print - Apr 25 2017

Fingerprint

Digoxin
Heart Failure
Neoplasms
Cell Line
Breast Neoplasms
Cohort Studies
Safety
Cardiac Glycosides
Precision Medicine
National Health Programs
Liver Neoplasms
Treatment Failure
Taiwan
Uncertainty
Cause of Death
Lung Neoplasms
Retrospective Studies
Databases

Keywords

  • Journal Article

Cite this

Risk of cancer in patients with heart failure who use digoxin : a 10-year follow-up study and cell-based verification. / Chung, Min-Huey; Wang, Yi Wen; Chang, Yung Lung; Huang, Shih Ming; Lin, Wei Shiang.

In: Oncotarget, 25.04.2017.

Research output: Contribution to journalArticle

@article{2465b879c22142f6a96b6311a6bf3189,
title = "Risk of cancer in patients with heart failure who use digoxin: a 10-year follow-up study and cell-based verification",
abstract = "Heart failure (HF) is the leading cause of death in the world and digoxin remains one of the oldest therapies for HF. However, its safety and efficacy have been controversial since its initial use and there is uncertainty about its long-term efficacy and safety. Recently, the repositioning of cardiac glycosides is to function in anti-tumor activity via multiple working pathways. It is interesting to compare the potential effects of digoxin in clinical patients and cell lines. First, we analyze patient information retrieved from the National Health Insurance Research database of Taiwan between January 1, 2000 and December 31, 2000. This retrospective study included a study cohort (1,219 patients) and a comparison cohort. Our analytical data suggested that patients taking digoxin are at an increased risk of cancers, including breast, liver, and lung cancers, during the 10-year follow-up period. In contrast to the anti-tumor function of digoxin, we further examined the potential pathway of digoxin via the cell-based strategy using several breast cancer cell lines, including MCF-7, BT-474, MAD-MB-231, and ZR-75-1. Digoxin consistently exerted its cytotoxicity to these four cell lines with various range of concentration. However, the proliferation of ZR-75-1 cells was the only cell lines induced by digoxin and the others were dramatically suppressed by digoxin. The responsiveness of SRSF3 to digoxin might be involved with cell-type differences. In summary, we combined a cohort study for digoxin treatment for HF patients with a cell-based strategy that addresses the translation issue, which revealed the complexity of personalized medicine.",
keywords = "Journal Article",
author = "Min-Huey Chung and Wang, {Yi Wen} and Chang, {Yung Lung} and Huang, {Shih Ming} and Lin, {Wei Shiang}",
year = "2017",
month = "4",
day = "25",
doi = "10.18632/oncotarget.17410",
language = "English",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",

}

TY - JOUR

T1 - Risk of cancer in patients with heart failure who use digoxin

T2 - a 10-year follow-up study and cell-based verification

AU - Chung, Min-Huey

AU - Wang, Yi Wen

AU - Chang, Yung Lung

AU - Huang, Shih Ming

AU - Lin, Wei Shiang

PY - 2017/4/25

Y1 - 2017/4/25

N2 - Heart failure (HF) is the leading cause of death in the world and digoxin remains one of the oldest therapies for HF. However, its safety and efficacy have been controversial since its initial use and there is uncertainty about its long-term efficacy and safety. Recently, the repositioning of cardiac glycosides is to function in anti-tumor activity via multiple working pathways. It is interesting to compare the potential effects of digoxin in clinical patients and cell lines. First, we analyze patient information retrieved from the National Health Insurance Research database of Taiwan between January 1, 2000 and December 31, 2000. This retrospective study included a study cohort (1,219 patients) and a comparison cohort. Our analytical data suggested that patients taking digoxin are at an increased risk of cancers, including breast, liver, and lung cancers, during the 10-year follow-up period. In contrast to the anti-tumor function of digoxin, we further examined the potential pathway of digoxin via the cell-based strategy using several breast cancer cell lines, including MCF-7, BT-474, MAD-MB-231, and ZR-75-1. Digoxin consistently exerted its cytotoxicity to these four cell lines with various range of concentration. However, the proliferation of ZR-75-1 cells was the only cell lines induced by digoxin and the others were dramatically suppressed by digoxin. The responsiveness of SRSF3 to digoxin might be involved with cell-type differences. In summary, we combined a cohort study for digoxin treatment for HF patients with a cell-based strategy that addresses the translation issue, which revealed the complexity of personalized medicine.

AB - Heart failure (HF) is the leading cause of death in the world and digoxin remains one of the oldest therapies for HF. However, its safety and efficacy have been controversial since its initial use and there is uncertainty about its long-term efficacy and safety. Recently, the repositioning of cardiac glycosides is to function in anti-tumor activity via multiple working pathways. It is interesting to compare the potential effects of digoxin in clinical patients and cell lines. First, we analyze patient information retrieved from the National Health Insurance Research database of Taiwan between January 1, 2000 and December 31, 2000. This retrospective study included a study cohort (1,219 patients) and a comparison cohort. Our analytical data suggested that patients taking digoxin are at an increased risk of cancers, including breast, liver, and lung cancers, during the 10-year follow-up period. In contrast to the anti-tumor function of digoxin, we further examined the potential pathway of digoxin via the cell-based strategy using several breast cancer cell lines, including MCF-7, BT-474, MAD-MB-231, and ZR-75-1. Digoxin consistently exerted its cytotoxicity to these four cell lines with various range of concentration. However, the proliferation of ZR-75-1 cells was the only cell lines induced by digoxin and the others were dramatically suppressed by digoxin. The responsiveness of SRSF3 to digoxin might be involved with cell-type differences. In summary, we combined a cohort study for digoxin treatment for HF patients with a cell-based strategy that addresses the translation issue, which revealed the complexity of personalized medicine.

KW - Journal Article

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85021786364&origin=resultslist&sort=plf-f&src=s&nlo=&nlr=&nls=&sid=d6c4b65b901e8e4d113257428ae20451&sot=a&sdt=a&sl=36&s=AU-ID%28%22Chung%2c+Min+Huey%22+22953113600%29&relpos=7&citeCnt=0&searchTerm=

U2 - 10.18632/oncotarget.17410

DO - 10.18632/oncotarget.17410

M3 - Article

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

ER -